Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02692755 · ClinicalTrials.gov registry record · Phase 2
Palbociclib / Letrozole or Fulvestrant in African American Women With HR+ HER2- Breast Cancer
A Phase 2 study, sponsored by Georgetown University.
- Completed
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
NCT02692755 is a Phase 2 study that has completed, run by Georgetown University. The registered enrollment target is 35 participants.
The verdict
NCT02692755, a Phase 2 study, has completed, sponsored by Georgetown University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
Study Summary
This study aims to evaluate the hematological safety of palbociclib with letrozole and fulvestrant in African American women with hormone receptor positive HER2 negative advanced breast cancer. Hematological safety is a composite endpoint of episodes of febrile neutropenia and treatment discontinuation due to neutropenia according to current recommendations for management of neutropenia
Interventions
- DRUG Palbociclib + Letrozole or Fulvestrant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2016-09 |
| Est. Completion | 2021-03-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02692755
The ClinicalTrials.gov registry entry for NCT02692755 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Georgetown University, which has 227 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Palbociclib + Letrozole or Fulvestrant is the first listed.
NCT02692755 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02692755 about?
NCT02692755 is a clinical study titled "Palbociclib / Letrozole or Fulvestrant in African American Women With HR+ HER2- Breast Cancer". This study aims to evaluate the hematological safety of palbociclib with letrozole and fulvestrant in African American women with hormone receptor positive HER2 negative advanced breast cancer. Hematological safety is a composite endpoint of episodes of febrile neutropenia and treatment discontinuat...
What is the current status of trial NCT02692755?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2016-09. Estimated completion is 2021-03-23.
What interventions are being tested in trial NCT02692755?
The interventions under investigation include: Palbociclib + Letrozole or Fulvestrant (DRUG).
Who is sponsoring clinical trial NCT02692755?
This trial is sponsored by Georgetown University, which has 227 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.